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Aims: Functional and structural changes in pulmonary vasculature characterize pulmonary arterial hypertension
(PAH) and the prognosis of advanced PAH remains poor despite progress in pharmacotherapy. Adipose-derived
regenerative cells (ADRCs) promote cell regeneration at pathological sites and comprise a novel therapy for ail-
ments of various organs. We investigated the effects of ADRC therapy in rat models of monocrotaline (MCT)-in-
duced pulmonary hypertension (PH) and the underlying mechanisms.
Mainmethods:Ratswere assigned to Control andMCT groupswithout andwith (M/A) intravenous transfusion of
seven million ADRCs on day 7. We echocardiographically evaluated pulmonary hypertension as pulmonary ar-
tery ﬂow acceleration time (PAAT) and deceleration (PADc). Right ventricular (RV) systolic pressure was mea-
sured by catheterization on day 28 and then pathological changes in pulmonary vessels were assessed. We
analyzed PAH-associated gene expression on day 14 using real-time RT-PCR.
Key ﬁndings: Echocardiography and RV catheterization showed that ADRC therapy inhibited PH development
(assessed as PAAT, PADc, and RV systolic pressure) at day 28 (MCT vs.M/A, P b 0.05). Pulmonary vascular remod-
eling was also inhibited (vessel wall thickness: MCT vs. M/A, P b 0.01). Messenger RNA levels of endothelin (ET)
A and B receptors, ET-1 and transforming growth factor (TGF)-β increased in the lungs byMCT were suppressed
by ADRCs (MCT vs. M/A, P b 0.05).
Signiﬁcance: The development of PH was inhibited by ADRCs through suppressing changes in the expression of
genes associated with ET and TGF-β systems. We believe that ADRC therapy could serve as a novel strategy for
treating PH.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/ .0/).3Introduction
Pulmonary arterial hypertension (PAH) is a debilitating chronic disor-
der of the lungs that is characterized by perpetually elevated blood pres-
sure in the pulmonary vasculature (Galie et al., 2009). The cause of PAH is
often idiopathic, but it can also arise secondarily due to medical condi-
tions such as collagen disease, heartmalformations or viral infections. Ge-
netic and epigenetic risk factors have also been linked to PAH
pathogenesis (Loscalzo, 2001), but, all known causes of PAH are associat-
ed with endothelial dysfunction, vasoconstriction and pulmonary vessel
remodeling.
Endothelial dysfunction is an early component of the pulmonary hy-
pertensive process, during which an imbalance is created between vaso-
dilators such as nitric oxide (NO) and prostacyclin, and vasoconstrictors
such as endothelin, thromboxane A2 and serotonin (Morrell et al.,
2009). This imbalance leads to a cascade of events that results in thevascular Medicine, Nagasaki
Sakamoto, Nagasaki 852-8501,
ura).
. This is an open access article underhyper-proliferation of pulmonary smooth muscle cells, the activation of
lung ﬁbroblasts, the induction of thromboticmediators and inﬂammatory
cytokine release, all of which increase vascular resistance and pressure.
One factor that is associated with endothelial dysfunction and vascular
impairment is the endothelin system. Endothelin-1 (ET-1), a peptide pro-
duced mainly by endothelial cells, was discovered in 1988 and it is a po-
tent vasoconstrictor and smooth muscle cell mitogen (Yanagisawa et al.,
1988). The ET-1 system is activated in both the plasma and lung tissues
of patients with PAH and in animal models of pulmonary hypertension
(PH).
Pulmonary arterial hypertension is refractory to most conventional
pharmacological therapies. Stem cell therapy might constitute a novel
treatment modality for patients with PH. Mesenchymal stem cells
(MSC) are unique in that they are pluripotent and can secrete paracrine
factors that improve damaged tissue (Passier and Mummery, 2003).
One such novel potential therapy for PH lies within the regenerative
properties of easily accessible and abundant adipose tissue-derived
stem and regenerative cells (ADRCs) that can be used in real-time, au-
tologous applications. Here, we investigated the effects of ADRC therapy
on PH and explored the underlyingmechanisms in a ratmodel ofmono-
crotaline (MCT)-induced PH.the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/ .0/).3
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Isolation of ADRCs
We isolated ADRCs from 13- to 14-week-old maleWistar rats (200–
250 g) as described with minor modiﬁcations (Angelini et al., 2011;
Feng et al., 2010). Brieﬂy, inguinal subcutaneous adipose tissue was re-
moved, minced and digested with 0.1% collagenase (Sigma-Aldrich, St.
Louis, MO,USA) for 40±5min at 37 °C. The ADRC fractionwas separat-
ed by centrifugation at 600 ×g for 5 min and sequentially passed
through 100- and 40-μm Falcon™ cell strainers (BD Biosciences, San
Jose, CA, USA). The ADRCs were washed in phosphate-buffered saline
(PBS) and resuspended (7.0 × 106/mL) in PBS. Some ADRCs were la-
beled with the cross-linkable membrane dye CM-DiI (Invitrogen™,
Carlsbad, CA, USA) as described in the manufacturer's protocol.
Flow cytometric analysis of ADRC
Adipose-derived regenerative cells resuspended in staining buffer
were incubated for 10 min at 4 °C with antibodies to block non-
speciﬁc binding and then for 30 min at 4 °C with CD45FITC (554878),
CD31PE (555027) and CD90PE (551401) (all from BD Pharmingen,
San Diego CA, USA) for ﬂow cytometry. The cells were washed twice
with cold Dulbecco's PBS, ﬁxed using FACS Lysing Solution (BD Biosci-
ences) and then analyzed on a FACSAria using FACSDiva software (BD
Biosciences).
Colony forming unit-ﬁbroblast (CFU-F) assay
CFU-F assay was performed as described by Hayashi et al. (2008).
Brieﬂy, ADRCs were seeded at a density of 1 × 103 nucleated cells/cm2
in 6-well plates and incubated in Dulbecco's Modiﬁed Eagle Medium
(DMEM) (Sigma-Aldrich)with 10% fetal bovine serum(FBS) (Sigma-Al-
drich). Mediumwas changed every 3–4 days. Six days after plating, col-
onies were stained with Crystal Violet (Wako, Osaka, Japan) and
counted. Only cell aggregates containingmore than 50 cells were scored
as a colony. The CFU is deﬁned as colonynumber per 100 nucleated cells
seeded.
Animal models
Monocrotaline (Sigma-Aldrich) was dissolved in 1 N HCl. The pH
was neutralized with 1 N NaOH, and the volume was adjusted with
PBS to achieve a concentration of 15 mg/mL. Eight week-old Wistar
rats weighing 225–250 g (Japan SLC Inc., Shizuoka, Japan) were subcu-
taneously injected with a bolus of MCT (50 mg/kg) or an equal volume
of PBS (Control group). All rats were weighed twice weekly during the
study and analyses proceeded until 28 days afterMCT or sham injection.
The Experimental Animal Committee at the Biomedical Research Center
Division of Comparative Medicine Center for Frontier Life Sciences at
Nagasaki University approved the experimental protocols and animal
care methods applied in the study.
Experimental groups
All experiments proceeded in a blinded manner to evaluate the ef-
fects of ADRC therapy. One week after MCT injection, the rats were ran-
domly assigned to one group that received 1 mL of PBS (MCT group) or
7.0 × 106 ADRC (M/A group) via the caudal vein. Control rats received
neither MCT nor ADRC (Control). Various types of cells in the range of
4.0 × 106 to 2.0 × 107 have been injected into the caudal vein as stem
cell therapy for PH in previous studies (Angelini et al., 2011; Kim et al.,
2012). Therefore, the amount of ADRCs injected herein was within
this range.Echocardiography
The rats were examined by transthoracic echocardiography using a
ProSound Alpha 7 ultrasound device (Hitachi-ALOKA Medical, Tokyo,
Japan) with a 13.0 MHz linear transducer. Pulmonary artery ﬂow was
measured using pulsed wave Doppler sonography with a sample gate
of 1.0mmat the level of the pulmonary valve but signals for pulmonary
artery ﬂow acceleration time (PAAT) and deceleration (PADc) were de-
termined at the right ventricular outﬂow tract and opening and closing
clicks of the pulmonary valve were avoided.We deﬁned PAAT as the in-
terval from onset to the maximal velocity of forward pulmonary artery
ﬂow and PADc as the ﬁrst linear deceleration period after maximal ve-
locity (Koskenvuo et al., 2010).
Measurement of right ventricular systolic pressure and hypertrophy
Twenty-eight days after MCT injection, the rats were anesthetized
with isoﬂurane and a 3-Fr tube was inserted via the right jugular vein
into the right ventricle (RV) to measure RV pressure using a PowerLab
2/26 with BP Amp (ADInstruments, Colorado Springs, CO, USA) under
a closed chest. The position of the catheter in RV was conﬁrmed by
the waveform. Data were analyzed using the Chart program supplied
with the Power Lab system. Right ventricular hypertrophywas assessed
by weighing the RV separately from the left ventricle (LV)with the sep-
tal wall (S).
Histological studies
After measuring the RV systolic pressure, the rats were sacriﬁced
with an overdose of pentobarbital sodium and several tissues including
the lungs, heart and liver were ﬁxed with 4% paraformaldehyde for
morphological analysis. Parafﬁn-embedded sections were processed
for hematoxylin–eosin (HE) and Elastica van Gieson stain (EVG) for op-
tical microscopic studies. The remodeling of pulmonary arterioles was
analyzed using the Saharamethod (Sahara et al., 2007) inwhich the ex-
ternal diameter andmedial wall thickness weremeasured in 30muscu-
lar arterioles (b100 μm external diameter) per lung section using a
computer-based image analysis system comprising a BZ-9000 ﬂuores-
cence and opticalmicroscope (KEYENCE, Tokyo, Japan). The ratio ofme-
dial thickness was calculated as: medial wall thickness × 2 / external
diameter.
Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assays proceeded using MK500 in-situ apoptosis detection
kits (Takara Bio Inc., Otsu, Shiga, Japan) according to themanufacturer's
protocol. The number of TUNEL-positive cells was counted and aver-
aged in 10 ﬁelds under a light microscope at ×200 magniﬁcation, and
representative ﬁelds were photographed.
Some of the tissues were ﬁxed with 4% formaldehyde that was in-
creased to 30% over 4 days and then immersed in OCT compound
(Sigma-Aldrich). The tissues were frozen in liquid nitrogen and stored
at −80 °C. Each section was cut into 7- to 10-μm slices. The survival
of ADRCs in the lung tissue was conﬁrmed by the presence of DiI-
labeled cells. Immunoﬂuorescence staining proceeded using a 1:200 di-
lution of FITC-conjugated mouse monoclonal anti-rat alpha smooth
muscle actin (SMA) antibody (Sigma-Aldrich) or a 1:50 dilution of
mouse monoclonal anti-rat PECAM-1 (CD31) antibody (Millipore,
Darmstadt, Germany) with a 1:1000 dilution of FITC-conjugated goat
anti-mouse IgG antibody (Millipore). Nuclei were stained with DAPI
(Vector Laboratories Inc., Burlingame, CA, USA).
Real-time reverse transcribed-polymerase chain reaction (RT-PCR)
The rats were sacriﬁced with an overdose of pentobarbital and the
upper lung lobe was removed and immersed in RNA later for 24 h and
frozen at−80 °C for PCR. The lung tissuewas used for RT-PCR to analyze
gene expressions.
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Germany) and cDNAwas reverse transcribed using PrimeScript™RT re-
agent kits (Takara Bio Inc.) as described (Vernal et al., 2008). ThemRNA
levels of ET-1, endothelin A (ETA) receptor, endothelin B (ETB) receptor,
interleukin (IL)-6, IL-10, vascular endothelial growth factor (VEGF), he-
patocyte growth factor (HGF), connective tissue growth factor (CTGF),
transforming growth factor beta (TGF-β) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were determined using real-time
quantitative PCR. Forward and reverse primers were designed (Supple-
mental Table 1) using Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/
primer3). Reference gene candidateswere ampliﬁed by real-time quan-
titative PCR using 10 μL of SYBR Premix Ex Taq (Takara Bio Inc.), 2 μL of
diluted reverse transcription product, 0.4 μL of forward and reverse
primer and 7.2 μL of DNase/RNase-free water in a total volume of
20 μL. Ampliﬁcation proceeded in a LightCycler 480 (Roche Applied Sci-
ence, Basel, Switzerland) with initial polymerase activation at 95 °C for
10min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. There-
after, the speciﬁcity of ampliconswas veriﬁed bymelting curve analysis
(60 °C to 95 °C). Fluorescent signals were normalized to an internal ref-
erence and the threshold cycle (Ct) was set within the PCR exponential
phase. Relative gene expression levels were calculated by comparing
cycle times for each target PCR. The Ct values of target mRNAwere nor-
malized by subtracting that of GAPDH to give theΔCt value. Relative ex-
pression levels were calculated using the equation:
relative gene expression = 2−(ΔCtsample − ΔCtcontrol).
Statistical analysis
Results are expressed as means ± standard deviation. Intergroup
comparisons were analyzed using one-way analysis of variance follow-
ed by Tukey's test. A P value of b0.05 was considered statistically signif-
icant. All data were statistically analyzed using Stat Flex ver. 6.0
software (Artech Ltd., Osaka, Japan).
Results
Characterization of ADRCs
The yield of fresh ADRCs isolated from pooled rat adipose tissues
(n = 8) was 1.15± 0.34 × 106/g. Flow cytometry (N= 3) showed that
ADRCs comprised an average of 9.4% CD45+ cells (blood and tissue-
derived leucocytes), 1.7% cells expressed endothelial cell markers
(CD45−/CD31+) (Supplemental Fig. 1B) and 18.5% expressed CD90+/
CD45− (Supplemental Fig. 1C) that are surface markers of stromal
cells. We further examined the colony-forming capability of ADRCs by
CFU-F assay (Supplemental Fig. 1D). The CFU-F for ADRCs was 5.7 ±
2.3/100 nucleated cells.
Gains in body weight and mortality
Gains in body weight signiﬁcantly decreased in the MCT and M/A
groups compared with the Control group during the study period.
More weight tended to be gained by the M/A, than the MCT group
(Control vs. MCT and M/A: 61.9 ± 6.0 vs. 16.8 ± 27.3 and 37.6 ±
10.9 g, P b 0.01 for both; MCT vs. M/A, 16.8 ± 27.3 vs. 37.6 ±
10.9 g, P = 0.06) (Supplemental Table 2). Three of 13 rats died in
the MCT group, whereas all rats remained alive in the Control and
M/A groups during the study period. However, Kaplan–Meier analy-
sis showed no statistically signiﬁcant difference in mortality rates
among the three groups (data not shown).
ADRCs suppress PH induced by MCT
The ratswith PHwere assessed by echocardiographyat baseline, and
at 21 and 28 days after MCT injection. The blood ﬂow of pulmonary ar-
teries in the MCT group resulted in more triangular, dagger-shapedDoppler signals. The blood ﬂow of pulmonary arteries in the M/A
groupwas almost normal, suggesting that the high resistance in the pul-
monary artery had become attenuated after cell transplantation
(Fig. 1A). The PAAT was signiﬁcantly shorter in the MCT, than in the
Control group on days 21 and 28 (day 28: 20.5 ± 3.2 vs. 30.0 ±
4.3 ms, P b 0.01). Treatment with ADRCs signiﬁcantly lengthened the
PAAT on day 28 (MCT vs. M/A, 20.5 ± 3.2 vs. 23.7 ± 3.6 ms, P b 0.05).
The PADc was signiﬁcantly increased in the MCT, compared
with the Control group on days 21 and 28 (day 28: 1434 ± 412 vs.
717 ± 193 cm/s2; P b 0.01). Treatment with ADRCs signiﬁcantly
shortened the PADc on day 28 (MCT vs. M/A, 1434 ± 412 vs. 904 ±
229 cm/s2, P b 0.01; Fig. 1B).
Right ventricular pressure was measured by catheterization in all
groups on day 28 afterMCT injection. Right ventricular systolic pressure
was signiﬁcantly elevated in theMCT, comparedwith the Control group
(37.2 ± 5.1 vs. 20.8 ± 3.4 mm Hg, P b 0.01). Treatment with ADRCs
inhibited this increase in RV systolic pressure (MCT vs. M/A, 37.2 ±
5.1 vs. 29.9 ± 6.6 mm Hg, P b 0.05; Fig. 1C). The ratio of RV/LV plus S,
an index of RV hypertrophy, was elevated in the MCT, compared with
the Control group (0.37 ± 0.15 vs. 0.22 ± 0.04, P b 0.05). However,
the RV/LV plus S did not signiﬁcantly differ between the MCT and M/A
groups (Fig. 1D).
ADRCs improved pulmonary artery remodeling induced by MCT
In line with the hemodynamic data, HE and EVG staining conﬁrmed
that ADRC transplantation attenuated the obliterative remodeling of the
small arteries that started in the lungs after MCT injection. The small ar-
teries in theMCT group featuredmedial hypertrophy and a hyperplastic
response in the pulmonary arterioles (Fig. 2A). The ratio of medial wall
thickness to the external diameter of the pulmonary artery was signiﬁ-
cantly increased in the MCT, compared with the Control group on day
28 (0.44±0.04 vs. 0.17± 0.04, P b 0.01). The ratio ofmedialwall thick-
ening of the pulmonary artery was signiﬁcantly decreased in the M/A
group compared with the MCT group on day 28 (0.31 ± 0.05 vs. 0.44 ±
0.04, P b 0.01; Fig. 2B).
We counted the apoptotic cells in lung tissues (Supplemental
Fig. 2A) and found signiﬁcantly more apoptotic cells in the MCT, than
in the Control group (2.3 ± 1.2 vs. 0.4 ± 0.2, P b 0.05). However, the
number of apoptotic cells did not signiﬁcantly differ between the MCT
and M/A groups (Supplemental Fig. 2B).
Identiﬁcation of transplanted ADRC
DiI-positive cells in the lungs that emitting red ﬂuorescence at seven
days after ADRC transplantation (Fig. 2C and F) were often located near
αSMA- (Fig. 2D) and CD31- (Fig. 2G) positive cells that emitted green
ﬂuorescence. We counted 4.52 ± 2.56 ADRCs in one ×200 power mag-
niﬁcation ﬁeld. However, the cells emitting red and green ﬂuorescence
were not colocalized (Fig. 2E andH), suggesting thatmost intravenously
implanted ADRCs did not differentiate into vascular endothelial or
smooth muscle cells in vivo. Red ﬂuorescence was also emitted by the
liver but not the heart of ADRC treated rats.
Gene expression analysis in the lung
Onday 14 afterMCT injection,mRNA levels of ET systemcomponents
(ET-1, ETA receptor and ETB receptor) and TGF-β in the lungs were sig-
niﬁcantly higher in the MCT, than the Control group (P b 0.05; Fig. 3A–
D). These increases were inhibited by ADRCs (MCT vs. M/A, P b 0.05;
Fig. 3A–D). Levels of IL-6 mRNA were increased in the MCT, compared
with the Control group, but they were not inhibited by ADRCs
(Fig. 3E). On the other hand, MCT did not signiﬁcantly change mRNA
levels of IL-10, CTGF, HGF and VEGF, whereas the level of IL-10 mRNA
was increased in the M/A, compared with the Control group (Fig. 3F–I).
Fig. 1. Therapy with ADRCs attenuated pulmonary hypertension in MCT-induced lung injury. (A) PAAT and PADc as surrogates for mean pulmonary artery pressure measured by Pulsed
Wave-Doppler echocardiography. Representative ﬂow pattern of pulmonary artery. (B) PAAT and PADc afterMCT injection in Control (n= 10), MCT (n= 12) andM/A (n= 13) groups.
(C) RV systolic pressure at 28 days afterMCT injection (n= 10). (D) Ratio of RV weight/left ventricular plus septal weight (n= 10). Data are shown asmeans± SEM. *P b 0.05, †P b 0.01
MCT vs. Cont; ‡P b 0.05, §P b 0.01 MCT vs. M/A; ¶P b 0.01 M/A vs. Cont.
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We investigated the effects of ADRC therapy in a rat model of PH in-
duced by MCT. We found that ADRC therapy signiﬁcantly inhibited the
progression of hemodynamic parameters assessed by right heart cathe-
terization and echocardiography, vascular remodeling and the gene ex-
pression of ET-1, ETA receptor, ETB receptor and TGF-β in the lungs.
Regenerative and gene therapy has recently become a global re-
search focus, but stem cell research remains in its infancy, and treat-
ment for PH has not yet been standardized. Therefore, further
experimental investigations into a safe and practical strategy for
treating PH are urgently required. Several studies have assessed the
ability of stem cell therapy using MSC and endothelial progenitor cells
to protect against PH. For example, Zhao et al. (2005) found that rat en-
dothelial progenitor cells exerted a protective effect in a ratmodel of PH
induced by MCT and that this effect was enhanced when the cells were
transfected with the eNOS gene. Luan et al. (2012) also found a protec-
tive effect ofMSC though a paracrinemechanism in a PHmodel induced
by high ﬂow.We also found that ADRC therapy protects against PH, but
we did not directly compare ADRC therapywith other types of stem cell
therapy such as endothelial progenitor cells or MSC, and thus whether
or not ADRC therapy is more effective than these therapies remains a
topic for future study. However, large quantities of ADRC, that do not re-
quire expansion ex vivo, can be isolated by minimally invasive liposuc-
tion thus rendering them an appealing and practical source for
immediate cell-based therapies (Fraser et al., 2004; Strem andHedrick, 2005). The development of PH was inhibited by ADRCs at
least in part, through inhibiting the expression of genes associated
with the ET system. Plasma levels of ET-1 are elevated in patients with
PH (Stewart et al., 1991), and ET-1 levels correlate with pulmonary ar-
terial pressure, pulmonary artery oxygen saturation and pulmonary
vascular resistance (Cacoub et al., 1997; Giaid et al., 1993). Levels of
ET-1 are also increased in the lungs of animal models of PH (Kim et al.,
2012). Levels of ET-1 can be modulated by TGF-β in human pulmonary
microvascular endothelial cells in vitro and the enhanced stimulatory
effects of TGF-β might lead to the vascular abnormalities associated
with PH (Newman et al., 2008). Lambers et al. (2013) reported that
ET-1 also activates pulmonary artery smooth muscle cells, and that
the synergistic effects of ET-1 and TGF-βmediate vascular remodeling
though ERK1/2 MAPK kinesis. Since we detected ADRCs in the lung at
day 14 and hemodynamic differences between days 14 and 21, we con-
sidered that ADRCs exerted therapeutic effects during the early phase of
MCT-induced PH. Therefore, we assessed mRNA concentrations of the
cytokines and growth factors that are involved in the process of PH de-
velopment on day 14 using the RT-PCR. We then examined histology of
the lung and heart tissues at day 28. The present study found that ADRC
therapy might attenuate vascular remodeling by reducing the expres-
sion of genes associated with both the TGF-β and ET systems.
The ADRC population comprised various types of cells. About 41.6%
and 3.4% of fresh ADRCs express mesenchymal and endothelial cell
markers, respectively (Feng et al., 2010) and 18.5% and 1.7% of our
ADRC population expressed surface markers of stromal cells and
Fig. 2. Effect of ADRCs onMCT-induced vessel wall thickness and identiﬁcation of transplanted ADRCs. (A) Representativemicrophotographs of pulmonary vessels from Control, MCT and
M/A groups (n= 5–6 per group; scale bar, 40 μm). (B) Analysis and quantitation of vessel wall thickness. Data are shown asmeans± SEM. *P b 0.01 MCT vs. Cont; †P b 0.01MCT vs. M/A.
(C) and (F) Labeled ADRCs around lung vessels at seven days after transplantation. (N= 4; scale bar, 50 μm). (D) GreenαSMA staining indicates smooth muscle cells; (G) CD31 (green)
staining indicates endothelial cells; (E) and (H) merged images of DAPI staining (blue) indicate nuclei.
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ported to be stem cells (Hayashi et al., 2008) and 5% of our ADRCs
were considered as stem cells from CFU-F assay. Thus, we consider
that our population of ADRCs was similar to previous reports.
Several investigators have described a paracrine mechanism of
ADRC therapy in various experimental models (Harada et al., 2013;
Suganuma et al., 2013). The expression of several growth factors such
as VEGF, HGF and insulin-like growth factor (IGF)-1 by ADRCs after
acute myocardial infarction in rats indicated that these cells promote
angiogenesis and exert anti-apoptotic/necrotic effects via a paracrine
mechanism (Schenke-Layland et al., 2009). Furthermore, ADRCs down-
regulate the expression of inﬂammation-related genes such as IL-6 and
chemokine (C-X-C motif) ligand 2 (CXCL2), and signiﬁcantly reduce in-
ﬂammation after acute kidney injury in rats (Feng et al., 2010).
Angelini et al. (2011) reported that stem cell therapy using adipose
tissue stromal vascular fraction (SVF) induced positive pulmonary vas-
cular remodeling, and improved neurohormonal proﬁles as well as he-
modynamic effects in rat models of PH. That study also found that
treatment with SVF prevents increases in levels of inﬂammatory
serum cytokines. These results agree with our study. In addition, we
also examined the gene expressions associated with TGF-β and ET sys-
tems in the lung tissue. Then we found that ADRC therapy attenuated
vascular remodeling though reducing the expression of genes associat-
ed with the TGF-β and ET systems without changing angiogenesis. The
levels of IL-6 were signiﬁcantly increased in the MCT group and thoseof IL-10 were increased in the M/A group compared with the Control
group, suggesting the anti-inﬂammatory effect of ADRCs. However, pre-
cisely howADRC suppresses the expression of genes associatedwith the
TGF-β and ET systems remains unknown.
The signiﬁcance of apoptosis in the pathogenesis or treatment of PH
is controversial. Li et al. (2014) reported that apoptosis of endothelial
cells in the lung tissue increased in MCT-induced PH, which triggered
smooth muscle cell growth, suggesting that apoptosis of endothelial
cells plays a role in the development of PH. Akagi et al. (2013) reported
that high-dose prostaglandin (PG) I2 induces apoptosis in pulmonary
artery smooth muscle cells from the patients with IPAH in association
with beneﬁcial effects of PGI2. Although apoptotic cells were increased
in theMCTgroup,we could not detect the anti-apoptotic effect of ADRCs
in this study. Thus, the anti-PH effect of ARDCs may not be mediated
through the anti-apoptotic effect.
This study has several limitations. The dose of injected MCT
(50 mg/kg) was relatively low to minimize animal mortality. Several
studies that have used 60 mg/kg of MCT induced a higher RV pres-
sure and a higher RV/LV + S ratio than we did (Baber et al., 2007;
Frasch et al., 1999; Lee et al., 2013). Thus, the amount of pressure over-
load in our model might not be sufﬁcient to cause RV remodeling.
Therefore, the increase in the RV/LV + S ratio in the MCT group was
small and we could not show the effects of ADRCs on RV remodeling.
We delivered ADRCs relatively soon after injectingMCT to show that
ADRC therapy could inhibit the progression of PH. Considering the
Fig. 3.Messenger RNA levels in the lung. Messenger RNA levels were normalized to GAPDH and are shown as ratios to those in Control lungs (n = 6). Values are shown as
means ± SEM. *P b 0.05 MCT vs. Cont; †P b 0.05 M/A vs. MCT; ‡P b 0.05 M/A vs. Control.
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various times after PH established should also be conﬁrmed.
The major limitation of this study is that the rat model of MCT-
induced PH partly differs from human PAH. Other rodent models of
PAH (Abe et al., 2010) and larger animals should be tested to open a
translational investigation of ADRC therapy on human pulmonary arte-
rial hypertension.
Lastly, we showed that transplanted ADRCs persisted in the lungs for
at least up to seven days after transplantation.Most of themwere locat-
ed in the stroma and a few were incorporated into the pulmonary ves-
sels. How long the transplanted ADRCs can survive in the lung and
maintain a paracrine effect remains unknown. We believe that transfu-
sion with ADRCs derived from GFP-positive rats instead of DiI staining
will help to address this issue in a future study.
Conclusion
The intravenous administration of ADRCs into rats with MCT-
induced PH inhibited PH development by suppressing changes in the
expression of genes associatedwith the TGF-β and ET systems. These re-
sults indicate that uncultured autologous ADRCs could serve as a novel
strategy for treating PH.
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